Document Detail


A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide.
MedLine Citation:
PMID:  16491283     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We describe a quadruple tetracycline labeling method that allows longitudinal assessment of short-term changes in bone formation in a single biopsy. We show that 1 month of hPTH(1-34) treatment extends the bone-forming surface, increases mineral apposition rate, and initiates modeling-based formation. INTRODUCTION: Iliac crest biopsy, with histomorphometric evaluation, provides important information about cellular activity in bone. However, to obtain longitudinal information, repeat biopsies must be performed. In this study, we show the capability to obtain short-term longitudinal information on bone formation in a single biopsy using a novel, quadruple labeling technique. MATERIALS AND METHODS: Two tetracycline labels were administered using a standard 3 days on, 12 days off, 3 days on format. Four weeks later, the tetracycline labeling was repeated using the same schedule but with a different tetracycline that can be distinguished from the first by its color under fluorescent light. Iliac crest biopsies were performed 1 week later and prepared undecalcified for histomorphometry. Indices of bone formation 1 month apart were measured and calculated using the two sets of labels. We used this method to investigate the early effects of teriparatide [hPTH(1-34)] treatment on bone formation. The results were compared with those from a group of control subjects who were quadruple-labeled, but did not receive hPTH(1-34). RESULTS: Treatment with hPTH(1-34) dramatically stimulated bone formation on cancellous and endocortical surfaces. This was achieved by both an increase in the linear rate of matrix apposition and extension of the bone-forming surface. New bone was deposited on previously quiescent surfaces (i.e., modeling-based formation), but a proportion of this could occur by encroachment from adjacent resorption cavities. CONCLUSIONS: A single transiliac crest bone biopsy, after sequential administration of two sets of tetracycline labels is a useful approach to study the short-term effects of anabolic agents on human bone. One month of hPTH(1-34) treatment extends the bone-forming surface, increases mineral apposition rate, and initiates modeling-based formation.
Authors:
Robert Lindsay; Felicia Cosman; Hua Zhou; Mathias P Bostrom; Victor W Shen; JoAnn D Cruz; Jeri W Nieves; David W Dempster
Related Documents :
546323 - In vitro measurement of phosphorus in small bone biopsies using 14 mev neutron activati...
3512133 - Calvarial hyperostosis: a benign x-linked recessive disorder.
6809293 - Tensile properties of antler bone.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2005-11-21
Journal Detail:
Title:  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research     Volume:  21     ISSN:  0884-0431     ISO Abbreviation:  J. Bone Miner. Res.     Publication Date:  2006 Mar 
Date Detail:
Created Date:  2006-02-21     Completed Date:  2006-04-14     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  8610640     Medline TA:  J Bone Miner Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  366-73     Citation Subset:  IM    
Affiliation:
Clinical Research Center, New York State Department of Health, Helen Hayes Hospital, West Haverstraw, New York 10993, USA. lindsayr@helenhayeshosp.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anabolic Agents / pharmacology,  therapeutic use*
Biopsy / methods
Bone Density Conservation Agents / pharmacology,  therapeutic use*
Female
Humans
Ilium / drug effects,  pathology*
Longitudinal Studies
Middle Aged
Osteogenesis*
Osteoporosis, Postmenopausal / drug therapy*,  pathology
Teriparatide / pharmacology,  therapeutic use*
Tetracycline / administration & dosage,  analysis*
Grant Support
ID/Acronym/Agency:
AR39101/AR/NIAMS NIH HHS
Chemical
Reg. No./Substance:
0/Anabolic Agents; 0/Bone Density Conservation Agents; 52232-67-4/Teriparatide; 60-54-8/Tetracycline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Complete recovery after the removal of an ectopic testicle in a case of primary reninism and retrope...
Next Document:  Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with ost...